---
title: "Veeva reaffirms $6 billion 2030 target, says quarter will meet or exceed guidance"
description: "Veeva reaffirmed a $6 billion revenue run rate for 2030 and said the October quarter will meet or exceed its $932-935 million guide, on a plan that explicitly excludes its AI products. Six banks raised targets the next day anyway; December 3 results are the first test of whether any AI revenue exists."
publisher: "The Inference"
section: "Platforms"
published: 2026-11-10T16:41:10.302Z
modified: 2026-11-10T16:41:10.302Z
canonical: https://theinference.org/article/veeva-reaffirms-6-billion-2030-target-says-quarter-will-meet-or-exceed-guidance
language: en
keywords: "Veeva Systems, Guidance, AI, Analyst Calls, Cloud Software"
---

# Veeva reaffirms $6 billion 2030 target, says quarter will meet or exceed guidance

> Veeva reaffirmed a $6 billion revenue run rate for 2030 and said the October quarter will meet or exceed its $932-935 million guide, on a plan that explicitly excludes its AI products. Six banks raised targets the next day anyway; December 3 results are the first test of whether any AI revenue exists.

[Veeva Systems](https://theinference.org/markets/companies/veeva-systems), which sells cloud software to the drug industry, put its addressable market at $30 billion at [its investor day on November 5](https://baseballnewssource.com/2026/11/07/veeva-systems-sticks-to-6-billion-revenue-goal-as-ai-expands-its-market-opportunity/11338728.html), up from $20 billion a year earlier, and credited the jump largely to industry-specific AI [1]. Chief executive Peter Gassner then declined to size what that AI might earn. [1]

## A $6 billion plan that leaves the AI out

The 2030 goal, a $6 billion annual revenue run rate against roughly $3.7 billion at the July quarter, is built from products Veeva already sells, chief financial officer Brian Van Wagener said [1]. It does not count Falcon, its line of software agents that do work for customers, or Vault AI, priced at 10 percent of a Vault subscription, or Aspen, its customer-relationship-management push beyond drugs [1]. None of the three has a financial target, and Falcon is live at only a few customers, its six- and seven-figure deals still pipeline. [1]

## The core has signed paper

[An 8-K securities filing dated November 6](https://www.sec.gov/Archives/edgar/data/1393052/000139305226000039/a2026veevainvestordayexv.htm) says the quarter ended October 31 will meet or exceed guidance of $932 million to $935 million in revenue and $417 million to $420 million in adjusted operating income. [2][3] The midpoint is about 15 percent growth, cooling from the 17.6 percent of the July quarter. [4] Full results and an update to fiscal 2027 guidance, now $1.64 billion of adjusted operating income, come on December 3. [1]

The rest of the core carries signatures: more than 200 customers live on Vault CRM, Veeva's own CRM platform, with 14 of the top 20 drugmakers signed and migrations running into 2029. [1] UCB, the Brussels drugmaker, committed worldwide on November 4, terms undisclosed. [5][6] [IQVIA](https://theinference.org/markets/companies/iqvia), the clinical-trials services giant, will run Veeva's clinical-operations software on all new studies within seven months, and Gassner sizes clinical-data sales through contract research organizations above $1 billion. [1]

*Chart: **Steady at 16-17% growth, and the 2030 target means $1.5 billion quarters** Line chart of Veeva quarterly revenue from April 2024 to the October 2026 guide, against the $1.5 billion quarterly pace implied by the 2030 target*

*Quarterly total revenue, US$ millions, fiscal quarters ended April 30, 2024, through July 31, 2026, from Veeva's SEC filings, plus the guided quarter ended October 31, 2026, marked as an estimate. Sources: Veeva SEC filings; Veeva 8-K exhibit, November 6, 2026. [2][4]*

## Six banks repriced the AI layer anyway

On November 6, [six banks lifted their targets](https://www.tradingview.com/news/tradingview:c6872065ee133:0-weekly-recap-veeva-s-6b-revenue-target-and-analyst-price-target-hikes/): [Jefferies](https://theinference.org/markets/companies/jefferies) to $375, RBC to $365, BTIG and Needham to $360, UBS and [Evercore](https://theinference.org/markets/companies/evercore) to $325. [8][9] [Truist](https://theinference.org/markets/companies/truist-financial) went to $360 from $305 and [Stifel](https://theinference.org/markets/companies/stifel) to $340. [10] The shares closed at $306.40 on November 9, up 37.26 percent this year, and the 29-analyst consensus of $323.07 sits just 5.44 percent above the price. [10]

What backs the raises so far are adoptions and demos rather than booked revenue: Roche, the world's fifth-largest drugmaker, is an early Falcon adopter for streamlining health-authority questions, and the widely shared demo of an agent building a clinical study in 45 minutes ran in [an article produced with Veeva's sponsorship](https://www.clinicaltrialvanguard.com/conference-coverage/the-45-minute-study-build-and-sanofis-push-to-automate-clinical-trials/). [1][7][11]

*Chart: **Eight target raises in one day, every one above the price** Bar chart of the eight analyst price targets raised for Veeva on November 6, 2026, against the November 9 closing price*

*Price targets for Veeva (NYSE: VEEV) in US dollars after the November 6, 2026, raises, against the November 9 close of $306.40. Sources: TradingView; MarketScreener. [7][8][9][10]*

## December 3 is the first checkpoint

The arithmetic of the reaffirmed path is modest: $3.7 billion to $6 billion by 2030 takes roughly 12 percent compound growth, against the mid-teens Veeva has printed for two years. [4] No filing shows a dollar of Falcon or Vault AI revenue yet; the December 3 guidance update is the first place one could appear, and the checkable question is whether the migration, the CRO data business and IQVIA carry the guide alone [4]. Six banks raised their targets on a market whose revenue Veeva itself says it cannot size.

## Takeaway

Veeva's $6 billion 2030 run-rate plan counts only products it already sells; the first place AI revenue could appear is the December 3 guidance update.

## Sources

1. [Baseball News Source, "Veeva Systems Sticks to $6 Billion Revenue Goal as AI Expands Its Market Opportunity", 7 November 2026](https://baseballnewssource.com/2026/11/07/veeva-systems-sticks-to-6-billion-revenue-goal-as-ai-expands-its-market-opportunity/11338728.html)
2. [SEC EDGAR, Veeva Systems Form 8-K Exhibit 99.1 (2026 Investor Day guidance slide), filed 6 November 2026](https://www.sec.gov/Archives/edgar/data/1393052/000139305226000039/a2026veevainvestordayexv.htm)
3. [Bullished, "Veeva Says Third-Quarter Results Will Meet Or Exceed Its Guidance Of $932 Million To $935 Million", 9 November 2026](https://www.bullished.co/veeva-says-third-quarter-results-will-meet-or-exceed-its-guidance-of-932-million-to-935-c2c99c5b/)
4. [Veeva Systems quarterly results from its SEC filings, ten quarters to the period ended 31 July 2026, retrieved 10 November 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393052)
5. [Veeva Systems press release, "UCB Selects Veeva Vault CRM", 4 November 2026](https://www.veeva.com/resources/ucb-selects-veeva-vault-crm/)
6. [QP Insight, "UCB signs up for Vault CRM as Veeva's CRM migration wave reaches Europe", November 2026](https://www.qpinsight.com/articles/veeva-ucb-vault-crm-move/)
7. [diginomica, "AI and Life Sciences: how Roche is making regulatory compliance faster and more efficient with Veeva", November 2026](https://diginomica.com/ai-and-life-sciences-how-roche-making-regulatory-compliance-faster-and-more-efficient-veeva)
8. [TradingView News, "BTIG maintains Veeva Systems at Buy, raises price target to $360 from $340", 9 November 2026](https://www.tradingview.com/news/tradingview:82a92f382bb6a:0-btig-maintains-veeva-systems-at-buy-raises-price-target-to-360-from-340/)
9. [TradingView News, "Weekly Recap: Veeva's $6B revenue target and analyst price-target hikes", 10 November 2026](https://www.tradingview.com/news/tradingview:c6872065ee133:0-weekly-recap-veeva-s-6b-revenue-target-and-analyst-price-target-hikes/)
10. [MarketScreener, "Truist Securities Adjusts Veeva Systems Price Target to $360 From $305, Maintains Buy Rating", 6 November 2026](https://www.marketscreener.com/news/truist-securities-adjusts-veeva-systems-price-target-to-360-from-305-maintains-buy-rating-ce785fd2db8cfe24)
11. [The Clinical Trial Vanguard, "The 45-Minute Study Build and Sanofi's Push to Automate Clinical Trials" (produced in partnership with Veeva Systems), November 2026](https://www.clinicaltrialvanguard.com/conference-coverage/the-45-minute-study-build-and-sanofis-push-to-automate-clinical-trials/)


---

Veeva reaffirms $6 billion 2030 target, says quarter will meet or exceed guidance — The Inference. Canonical: https://theinference.org/article/veeva-reaffirms-6-billion-2030-target-says-quarter-will-meet-or-exceed-guidance